Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Giancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA Abstract: Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinic...
Guardado en:
Autores principales: | Garcia GA, Ngai P, Mosaed S, Lin KY |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d67d8233ff134794a81313669bfa3f40 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018) -
Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension
por: Fang Y, et al.
Publicado: (2017) -
Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017) -
Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
por: Cantor E, et al.
Publicado: (2018) -
Incidence and Risk Factors of Ocular Hypertension/Glaucoma After Descemet Stripping Automated Endothelial Keratoplasty
por: Elalfy M, et al.
Publicado: (2021)